29 results on '"Drayson, Mark T"'
Search Results
2. Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival
3. Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
4. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial.
5. Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection
6. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
7. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
8. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)
9. The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions
10. Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? – response
11. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML)
12. Frequency of altered monoclonal protein production at relapse of multiple myeloma
13. IgM myeloma: a rare entity characterized by a CD20−CD56−CD117− immunophenotype and the t(11;14)
14. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival
15. Serum free light chains for monitoring multiple myeloma
16. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
17. MRC trial of alpha 2b-interferon maintenance therapy in first plateau phase of multiple myeloma
18. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
19. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial.
20. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
21. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests
22. A population-based study of the impact of dialysis on mortality in multiple myeloma
23. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial.
24. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)
25. IgM myeloma: a rare entity characterized by a CD20−CD56−CD117−immunophenotype and the t(11;14)
26. Response to: Serum free light chains for monitoring multiple myeloma
27. IgM myeloma: a rare entity characterized by a CD20−CD56−CD117− immunophenotype and the t(11;14).
28. MRC trial of α2b-interferon maintenance therapy in first plateau phase of multiple myeloma.
29. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.